Alzheimers. Alzheimer's disease
Conditions
Interventions
Intervention 1: In the "case group" The drug supplement is added to the previous drug (here, dopenzyl). The supplement includes iron (0.45 mg), cytidine (75 mg), uridine (75 mg), pantothenic acid (1.0
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
60 Years to 95 Years
Inclusion criteria
Inclusion criteria: patient with dementia and clinically diagnosed alzheimer's MMSE score at the beginning of the study range between 24 and 12 observing atrophic evidence in brain CTscan or brain MRI, and rule out other causes of my dementia, including reversible causes, or vascular dementia having decision making capacity to enter or exit the study
Exclusion criteria
Exclusion criteria: dissatisfaction for participation in study history of other neurological diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Result number of "MMSE" exam (maximum 30 points). Timepoint: before and after the 12week coarse of treatment. Method of measurement: interview with the patient.;ADL result number (activity of daily living) / maximum 6 points. Timepoint: before and after the 12week coarse of treatment. Method of measurement: interview with the patient. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Ahmad Chitsaz
Esfahan University of Medical Sciences
Outcome results
None listed